NCT01524666

Brief Summary

This is a nonblinded Case-only study that evaluates the effects of Agmatine Sulfate on small fiber peripheral neuropathy. Patients will be started on Agmatine sulfate (a metabolite of Arginine) and monitored for two months. Improvement will be noted on their response to the Neuropathic Pain Questionnaire. Additionally the investigators will note improvement by performing autonomic function testing at the beginning and end of the study.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
15

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Feb 2012

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 31, 2012

Completed
1 day until next milestone

Study Start

First participant enrolled

February 1, 2012

Completed
1 day until next milestone

First Posted

Study publicly available on registry

February 2, 2012

Completed
6.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2018

Completed
Last Updated

February 28, 2018

Status Verified

February 1, 2018

Enrollment Period

6.7 years

First QC Date

January 31, 2012

Last Update Submit

February 27, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Neuropathic Pain Questionnaire

    After 2 months

Secondary Outcomes (1)

  • QSART & ANSAR testing

    After 2 months

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Clinic patients at JFK Med CTR

You may qualify if:

  • Men and Women Ages 18-75 with symptoms of small Fiber Neuropathy and have been diagnosed via autonomic function testing and or skin biopsy

You may not qualify if:

  • Women who are pregnant or breast feeding, patients with history of substance abuse, and patients with myelopathy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

JFK Medical Center

Edison, New Jersey, 07712, United States

RECRUITING

Related Publications (2)

  • Keynan O, Mirovsky Y, Dekel S, Gilad VH, Gilad GM. Safety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. An Open-label, Dose-escalating Study Followed by a Randomized, Double-blind, Placebo-controlled Trial. Pain Med. 2010 Mar;11(3):356-68. doi: 10.1111/j.1526-4637.2010.00808.x.

    PMID: 20447305BACKGROUND
  • Rosenberg ML, Tohidi V, Sherwood K, Gayen S, Medel R, Gilad GM. Evidence for Dietary Agmatine Sulfate Effectiveness in Neuropathies Associated with Painful Small Fiber Neuropathy. A Pilot Open-Label Consecutive Case Series Study. Nutrients. 2020 Feb 23;12(2):576. doi: 10.3390/nu12020576.

Biospecimen

Retention: SAMPLES WITHOUT DNA

Skin Biopsy

MeSH Terms

Conditions

Peripheral Nervous System Diseases

Condition Hierarchy (Ancestors)

Neuromuscular DiseasesNervous System Diseases

Study Officials

  • Michael Rosenberg, M.D.

    JFK Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Michael Rosenberg, MD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

January 31, 2012

First Posted

February 2, 2012

Study Start

February 1, 2012

Primary Completion

October 1, 2018

Study Completion

October 1, 2018

Last Updated

February 28, 2018

Record last verified: 2018-02

Locations